SimplicityBio: A new CEO and a successful partnership

Please login or
register
07.02.2017

SimplicityBio appoints its Co-founder Matthew Hall as Chief Executive Officer (CEO). The start-up will keep focusing on discovering novel biomarkers for more robust and accurate diagnostics for its clients and partners. One example for a successful collaboration is the partnership with Minomic International. The two companies developed a new prostate cancer test.

Matthew Hall takes over the position from Miguel Barreto who now acts as CTO of the company. “As Chief Scientific Officer (CSO) at SimplicityBio so far, Matthew demonstrated ability to build a clear vision of how biology and bioinformatics can deliver value to clients and partners. His natural leadership and relationships with clients and partners makes him the right CEO to lead the company moving forward”, said Vincent Bieri, Chairman of the Board.

Miguel Barreto, former CEO and Co-founder of SimplicityBio will take product and innovation ownership as Chief Technology Officer (CTO). Miguel is the father of SimplicityBio’s technology and brings more than 10 years of experience in applied machine learning and bioinformatics.

Under its new CEO, SimplicityBio will keep focusing on discovering novel biomarkers for more robust and accurate diagnostics enabling its clients and partners to develop more efficient and cost effective drugs and treatments, in particular in the areas of oncology, cardiovascular diseases and osteoporosis.

New test for prostate cancer
One example for a successful collaboration is the partnership with Minomic International. From the collaboration of the two companies a new prostate cancer test was born that is being validated in US clinical studies. The results showed a reduction of the number of false positives to 2 in 10 tested men and gave clinicians the capacity to know if the prostate cancer is aggressive. These results were presented in 2016 at the First Global Summit on Precision Diagnosis for Prostate Cancer in Boston. The test will be launched in the US in 2017. MiCheck MIA results will enable doctors to do confirmatory biopsies with confidence that they are needed. More information about the collaboration can be found in a blog post by Matthew Hall.

Brad Walsh, CEO Minomic International, comments: "I have no hesitation in highly recommending SimplicityBio as a great partner. They have been with us in every step of our project over the last two years, from discovery of candidate biomarker signatures all the way through to their validation. Their unique platform delivered robust signatures that kept performing even when switching from plasma to serum and before being optimised. They have helped us extract the best from our data, exploring it fully in both the technical and commercial areas. This gave us the outcomes we needed and the confidence to raise funds and move forward. Without SimplicityBio's technology (and team support) it would not have been possible. Their responsiveness and commitment to understand our needs makes them a partner of choice"

0Comments

rss